Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous bone marrow mesenchymal stem cells (BM-MSCs) are multipotent stromal cells harvested from a patient's own bone marrow, processed, and re-administered to treat ST-segment elevation myocardial infarction (STEMI). Developed by the Affiliated Hospital of North Sichuan Medical College, this cell therapy is delivered via intracoronary injection into the infarct-related artery following percutaneous coronary intervention (PCI). The mechanism of action involves the secretion of paracrine factors that promote angiogenesis, reduce apoptosis of cardiomyocytes, and modulate the inflammatory response, ultimately aiming to improve left ventricular ejection fraction and reduce myocardial infarct size.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow mesenchymal stem cells (Affiliated Hospital of North Sichuan Medical College).